Suppression of AMF/PGI-mediated tumorigenic activities by ursolic acid in cultured hepatoma cells and in a mouse model

Molecular Carcinogenesis

Volumn 52, Issue 10, 2013, Pages 800-812

  Shih, Wen Ling ^a   Yu, Feng Ling ^b   Chang, Ching Dong ^a   Liao, Ming Huei ^a   Wu, Hung Yi ^a   Lin, Ping Yuan ^c  

^a NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^b TZU HUI INSTITUTE OF TECHNOLOGY   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

Author keywords

AMF PGI; Angiogenesis; Cisplatin; Hepatocellular carcinoma; Ursolic acid

Indexed keywords

BROXURIDINE; CISPLATIN; GLUCOSE 6 PHOSPHATE ISOMERASE; NOBILETIN; OLEANOLIC ACID; PROTEIN BAD; PROTEIN KINASE B; PROTEIN P85; STAT3 PROTEIN; STROMELYSIN; TANGERETIN; URSOLIC ACID;

ANGIOGENESIS; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CELL MIGRATION; CELL MOTILITY; COLONY FORMATION; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; HEPATOMA CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSACTIVATION; TUMOR GROWTH; TUMOR VOLUME;

AMF/PGI; ANGIOGENESIS; CISPLATIN; HEPATOCELLULAR CARCINOMA; URSOLIC ACID;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CISPLATIN; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLAVONES; FLUORESCENT ANTIBODY TECHNIQUE; GLUCOSE-6-PHOSPHATE ISOMERASE; HUMANS; IMMUNOPRECIPITATION; LIVER NEOPLASMS; LUCIFERASES; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 3; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OLEANOLIC ACID; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TRITERPENES; TUMOR CELLS, CULTURED;

MUS;

EID: 84884812977     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21919     Document Type: Article

References (66)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2:533-543.
2. Watanabe H, Takehana K, Date M, Shinozaki T, Raz A. Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. Cancer Res 1996; 56:2960-2963.
3. Kim JW, Dang CV. Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 2005; 30:142-150.
4. Beutler E, West C, Britton HA, Harris J, Forman L. Glucosephosphate isomerase (GPI) deficiency mutations associated with hereditary nonspherocytic hemolytic anemia (HNSHA). Blood Cells Mol Dis 1997; 23:402-409.
5. Ravindranath Y, Paglia DE, Warrier I, Valentine W, Nakatani M, Brockway RA. Glucose phosphate isomerase deficiency as a cause of hydrops fetalis. N Engl J Med 1987; 316:258-261.
6. Matsumoto I, Staub A, Benoist C, Mathis D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 1999; 286:1732-1735.
7. Baumann M, Kappl A, Lang T, Brand K, Siegfried W, Paterok E. The diagnostic validity of the serum tumor marker phosphohexose isomerase (PHI) in patients with gastrointestinal, kidney, and breast cancer. Cancer Invest 1990; 8:351-356.
8. Filella X, Molina R, Jo J, Mas E, Ballesta AM. Serum phosphohexose isomerase activities in patients with colorectal cancer. Tumour Biol 1991; 12:360-367.
9. Gong W, Jiang Y, Wang L, et al. Expression of autocrine motility factor correlates with the angiogenic phenotype of and poor prognosis for human gastric cancer. Clin Cancer Res 2005; 11:5778-5783.
10. Tsutsumi S, Hogan V, Nabi IR, Raz A. Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts. Cancer Res 2003; 63:242-249.
11. Tsutsumi S, Yanagawa T, Shimura T, et al. Regulation of cell proliferation by autocrine motility factor/phosphoglucose isomerase signaling. J Biol Chem 2003; 278:32165-32172.
12. Shih WL, Liao MH, Lin PY, et al. PI 3-kinase/Akt and STAT3 are required for the prevention of TGF-beta-induced Hep3B cell apoptosis by autocrine motility factor/phosphoglucose isomerase. Cancer Lett 2010; 290:223-237.
13. Onishi Y, Tsukada K, Yokota J, Raz A. Overexpression of autocrine motility factor receptor (AMFR) in NIH3T3 fibroblasts induces cell transformation. Clin Exp Metastasis 2003; 20:51-58.
14. Yu FL, Liao MH, Lee JW, Shih WL. Induction of hepatoma cells migration by phosphoglucose isomerase/autocrine motility factor through the upregulation of matrix metalloproteinase-3. Biochem Biophys Res Commun 2004; 314:76-82.
15. Wang L, Hou G, Xue L, Li J, Wei P, Xu P. Autocrine motility factor receptor signaling pathway promotes cell invasion via activation of ROCK-2 in esophageal squamous cell cancer cells. Cancer Invest 2010; 28:993-1003.
16. Ahmad A, Aboukameel A, Kong D, et al. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res 2011; 71:3400-3409.
17. Niinaka Y, Paku S, Haga A, Watanabe H, Raz A. Expression and secretion of neuroleukin/phosphohexose isomerase/maturation factor as autocrine motility factor by tumor cells. Cancer Res 1998; 58:2667-2674.
18. Funasaka T, Haga A, Raz A, Nagase H. Autocrine motility factor secreted by tumor cells upregulates vascular endothelial growth factor receptor (Flt-1) expression in endothelial cells. Int J Cancer 2002; 101:217-223.
19. Funasaka T, Haga A, Raz A, Nagase H. Tumor autocrine motility factor is an angiogenic factor that stimulates endothelial cell motility. Biochem Biophys Res Commun 2001; 285:118-128.
20. Tsutsumi S, Yanagawa T, Shimura T, Kuwano H, Raz A. Autocrine motility factor signaling enhances pancreatic cancer metastasis. Clin Cancer Res 2004; 10:7775-7784.
21. Shimizu K, Tani M, Watanabe H, et al. The autocrine motility factor receptor gene encodes a novel type of seven transmembrane protein. FEBS Lett 1999; 456:295-300.
22. Tsutsumi S, Gupta SK, Hogan V, Collard JG, Raz A. Activation of small GTPase Rho is required for autocrine motility factor signaling. Cancer Res 2002; 62:4484-4490.
23. Shih WL, Liao MH, Yu FL, Lin PY, Hsu HY, Chiu SJ. AMF/PGI transactivates the MMP-3 gene through the activation of Src-RhoA-phosphatidylinositol 3-kinase signaling to induce hepatoma cell migration. Cancer Lett 2008; 270:202-217.
24. Kanbe K, Chigira M, Watanabe H. Effects of protein kinase inhibitors on the cell motility stimulated by autocrine motility factor. Biochim Biophys Acta 1994; 1222:395-399.
25. Timar J, Silletti S, Bazaz R, Raz A, Honn KV. Regulation of melanoma-cell motility by the lipoxygenase metabolite 12-(S)-HETE. Int J Cancer 1993; 55:1003-1010.
26. Soker S, Kaefer M, Johnson M, Klagsbrun M, Atala A, Freeman MR. Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am J Pathol 2001; 159:651-659.
27. Haga A, Funasaka T, Niinaka Y, Raz A, Nagase H. Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression. Int J Cancer 2003; 107:707-714.
28. Fulda S. Modulation of apoptosis by natural products for cancer therapy. Planta Med 2010; 76:1075-1079.
29. Mehta RG, Murillo G, Naithani R, Peng X. Cancer chemoprevention by natural products: How far have we come? Pharm Res 2010; 27:950-961.
30. Shibata S. Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. J Korean Med Sci 2001; 16:S28-37.
31. Benavente-Garcia O, Castillo J, Alcaraz M, Vicente V, Del Rio JA, Ortuno A. Beneficial action of citrus flavonoids on multiple cancer-related biological pathways. Curr Cancer Drug Targets 2007; 7:795-809.
32. Sultana N, Ata A. Oleanolic acid and related derivatives as medicinally important compounds. J Enzyme Inhib Med Chem 2008; 23:739-756.
33. Liu J. Oleanolic acid and ursolic acid: Research perspectives. J Ethnopharmacol 2005; 100:92-94.
34. Tian Z, Lin G, Zheng RX, Huang F, Yang MS, Xiao PG. Anti-hepatoma activity and mechanism of ursolic acid and its derivatives isolated from Aralia decaisneana. World J Gastroenterol 2006; 12:874-879.
35. Gao X, Deeb D, Jiang H, Liu Y, Dulchavsky SA, Gautam SC. Synthetic triterpenoids inhibit growth and induce apoptosis in human glioblastoma and neuroblastoma cells through inhibition of prosurvival Akt, NF-kappaB and Notch1 signaling. J Neurooncol 2007; 84:147-157.
36. Pathak AK, Bhutani M, Nair AS, et al. Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol Cancer Res 2007; 5:943-955.
37. Achiwa Y, Hasegawa K, Udagawa Y. Regulation of the phosphatidylinositol 3-kinase-Akt and the mitogen-activated protein kinase pathways by ursolic acid in human endometrial cancer cells. Biosci Biotechnol Biochem 2007; 71:31-37.
38. Raphael TJ, Kuttan G. Effect of naturally occurring triterpenoids ursolic acid and glycyrrhizic acid on the cell-mediated immune responses of metastatic tumor-bearing animals. Immunopharmacol Immunotoxicol 2008; 30:243-255.
39. Morley KL, Ferguson PJ, Koropatnick J. Tangeretin and nobiletin induce G1 cell cycle arrest but not apoptosis in human breast and colon cancer cells. Cancer Lett 2007; 251:168-178.
40. Hirata Y, Masuda Y, Kakutani H, et al. Sp1 is an essential transcription factor for LPS-induced tissue factor expression in THP-1 monocytic cells, and nobiletin represses the expression through inhibition of NF-kappaB, AP-1, and Sp1 activation. Biochem Pharmacol 2008; 75:1504-1514.
41. Nagase H, Omae N, Omori A, et al. Nobiletin and its related flavonoids with CRE-dependent transcription-stimulating and neuritegenic activities. Biochem Biophys Res Commun 2005; 337:1330-1336.
42. Chen KH, Weng MS, Lin JK. Tangeretin suppresses IL-1beta-induced cyclooxygenase (COX)-2 expression through inhibition of p38 MAPK, JNK, and AKT activation in human lung carcinoma cells. Biochem Pharmacol 2007; 73:215-227.
43. Miyata Y, Sato T, Imada K, Dobashi A, Yano M, Ito A. A citrus polymethoxyflavonoid, nobiletin, is a novel MEK inhibitor that exhibits antitumor metastasis in human fibrosarcoma HT-1080 cells. Biochem Biophys Res Commun 2008; 366:168-173.
44. Sato T, Koike L, Miyata Y, et al. Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080 cells. Cancer Res 2002; 62:1025-1029.
45. Miyata Y, Sato T, Yano M, Ito A. Activation of protein kinase C betaII/epsilon-c-Jun NH2-terminal kinase pathway and inhibition of mitogen-activated protein/extracellular signal-regulated kinase 1/2 phosphorylation in antitumor invasive activity induced by the polymethoxy flavonoid, nobiletin. Mol Cancer Ther 2004; 3:839-847.
46. Pan MH, Chen WJ, Lin-Shiau SY, Ho CT, Lin JK. Tangeretin induces cell-cycle G1 arrest through inhibiting cyclin-dependent kinases 2 and 4 activities as well as elevating Cdk inhibitors p21 and p27 in human colorectal carcinoma cells. Carcinogenesis 2002; 23:1677-1684.
47. Zhang Y, Jayaprakasam B, Seeram NP, Olson LK, DeWitt D, Nair MG. Insulin secretion and cyclooxygenase enzyme inhibition by cabernet sauvignon grape skin compounds. J Agric Food Chem 2004; 52:228-233.
48. Ji WT, Wang YC, Lin FL, Liao MH, Shih WL, Liu HJ. Inhibitors of phosphatidylinositol 3-kinase and mTOR but not Akt enhance replication of bovine ephemeral fever virus. Vet J 2011; 187:119-123.
49. Aparecida Resende de Andrade F, Barcala CA, da Silva Faria MC, Kato FH, Cunha WR, Tavares DC. Antimutagenicity of ursolic acid and oleanolic acid against doxorubicin-induced clastogenesis in Balb/c mice. Life Sci 2006; 79:1268-1273.
50. Guevara AP, Amor E, Russell G. Antimutagens from Plumeria acuminata Ait. Mutat Res 1996; 361:67-72.
51. Shanmugam MK, Rajendran P, Li F, et al. Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice. J Mol Med (Berl) 2011; 89:713-727.
52. Hsu HY, Yang JJ, Lin CC. Effects of oleanolic acid and ursolic acid on inhibiting tumor growth and enhancing the recovery of hematopoietic system postirradiation in mice. Cancer Lett 1997; 111:7-13.
53. Hsu YL, Cho CY, Kuo PL, Huang YT, Lin CC. Plumbagin (5-hydroxy-2-methyl-1, 4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J Pharmacol Exp Ther 2006; 318:484-494.
54. Liu LZ, Fang J, Zhou Q, Hu X, Shi X, Jiang BH. Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: Implication of chemoprevention of lung cancer. Mol Pharmacol 2005; 68:635-643.
55. Pan SL, Guh JH, Peng CY, et al. YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models. J Pharmacol Exp Ther 2005; 314:35-42.
56. Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol 1998; 41:385-390.
57. Su J, Zhen YS, Qi CQ, Chen WJ. A fungus-derived novel nucleoside transport inhibitor potentiates the activity of antitumor drugs. Yao Xue Xue Bao 1994; 29:656-661.
58. Wakamatsu T, Nakahashi Y, Hachimine D, Seki T, Okazaki K. The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol 2007; 31:1465-1472.
59. Lin HY, Kao YH, Chen ST, Meng M. Effects of inherited mutations on catalytic activity and structural stability of human glucose-6-phosphate isomerase expressed in Escherichia coli. Biochim Biophys Acta 2009; 1794:315-323.
60. Shih WL, Kuo ML, Chuang SE, Cheng AL, Doong SL. Hepatitis B virus X protein inhibits transforming growth factor-beta -induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway. J Biol Chem 2000; 275:25858-25864.
61. Hsu YL, Kuo PL, Cho CY, et al. Antrodia cinnamomea fruiting bodies extract suppresses the invasive potential of human liver cancer cell line PLC/PRF/5 through inhibition of nuclear factor kappaB pathway. Food Chem Toxicol 2007; 45:1249-1257.
62. Lin JD, Lin PY, Chen LM, Fang WH, Lin LP, Loh CH. Serum glutamic-oxaloacetic transaminase (GOT) and glutamic-pyruvic transaminase (GPT) levels in children and adolescents with intellectual disabilities. Res Dev Disabil 2010; 31:172-177.
63. Wu HY, Chang CI, Lin BW, et al. Suppression of hepatitis B virus x protein-mediated tumorigenic effects by ursolic Acid. J Agric Food Chem 2011; 59:1713-1722.
64. Takeuchi A, Kaneko S, Matsushita E, Urabe T, Shimoda A, Kobayashi K. Interferon-alpha modulates resistance to cisplatin in three human hepatoma cell lines. J Gastroenterol 1999; 34:351-358.
65. Rooprai HK, Kandanearatchi A, Maidment SL, et al. Evaluation of the effects of swainsonine, captopril, tangeretin and nobiletin on the biological behaviour of brain tumour cells in vitro. Neuropathol Appl Neurobiol 2001; 27:29-39.
66. Liu J. Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 1995; 49:57-68.